Breaking News Instant updates and real-time market news.

HALO

Halozyme

$13.18

0.12 (0.92%)

, RHHBY

Roche

$31.49

-0.06 (-0.19%)

07:09
09/14/17
09/14
07:09
09/14/17
07:09

Halozyme licences new Enhanze target for $30M upfront payment from Roche

Halozyme (HALO) licensed its Enhanze drug-delivery technology to Roche (RHHBY) for exclusive development of an undisclosed therapeutic target. Halozyme will receive an initial $30M with the potential to earn additional payments of up to $160M subject to achievement of specified development, regulatory and sales-based milestones. Halozyme will also receive tiered, mid-single digit royalties on sales of commercialized products. The Halozyme/Roche relationship dates back to the original global collaboration and licensing agreement for the ENHANZE technology signed in 2006.

HALO

Halozyme

$13.18

0.12 (0.92%)

RHHBY

Roche

$31.49

-0.06 (-0.19%)

  • 25

    Sep

  • 30

    Nov

HALO Halozyme
$13.18

0.12 (0.92%)

01/05/17
PIPR
01/05/17
NO CHANGE
Target $20
PIPR
Overweight
Halozyme price target raised to $20 after pancreas cancer data at Piper Jaffray
Piper Jaffray analyst Charles Duncan raised his price target on Halozyme to $20 from $18, saying the company's "encouraging" Phase 2 data for its pancreas cancer combination treatment reduce the risk to the ongoing Phase 3 program for the combo. Duncan keeps an Overweight rating on Halozyme.
01/06/17
SBSH
01/06/17
DOWNGRADE
Target $14
SBSH
Neutral
Halozyme downgraded to Neutral from Buy at Citi
Citi analyst Joel Beatty downgraded Halozyme Therapeutics to Neutral saying the "mixed" Phase 2 pancreatic cancer data for PEGPH20 suggested the market opportunity is smaller than previously thought. The analyst believes the shares are now fairly valued. He keeps a $14 price target for the name.
03/30/17
DBAB
03/30/17
NO CHANGE
Target $17
DBAB
Buy
Halozyme price target raised to $17 from $15 at Deutsche Bank
Deutsche Bank analyst Andrew Peters raised his price target for Halozyme to $17 saying the positive, "unanimous and uncontroversial" FDA Advisory Committee meeting for Rituxan-SC highlights the "strong potential" for the broader Enhanze platform. The analyst reiterates a Buy rating on the shares.
04/17/17
BMOC
04/17/17
INITIATION
Target $14
BMOC
Market Perform
Halozyme initiated with a Market Perform at BMO Capital
BMO Capital initiated Halozyme with a Market Perform and a $714 price target.
RHHBY Roche
$31.49

-0.06 (-0.19%)

08/08/17
JEFF
08/08/17
NO CHANGE
Target $75
JEFF
Buy
FibroGen price target raised to $75 from $50 at Jefferies
Jefferies analyst Michael Yee raised his price target for FibroGen (FGEN) shares to $75 saying "significant value creation should occur now" after the company reported positive Phase II idiopathic pulmonary fibrosis lung data for FG-3019. The analyst believes the $5B market capitalization implied by his new price target could prove conservative. InterMune had comparable data and was acquired by Roche (RHHBY) for $8B, Yee tells investors in a research note. The analyst reiterates a Buy rating on FibroGen. The stock in premarket trading is up 59%, or $19.60, to $53.00.
08/23/17
WBLR
08/23/17
INITIATION
Target $107
WBLR
Outperform
AveXis initiated with an Outperform at William Blair
William Blair analyst Raju Prasad started AveXis (AVXS) with an Outperform rating and $107 fair value estimate, noting that the company's Phase I data for AVXS-101have continued to show a meaningful benefit in spinal muscular atrophy type 1. The analyst, who thinks AveXis has a high probability of receiving guidance for a potential regulatory filing following the company's end-of-Phase I meeting with the FDA, said AveXis could become an acquisition target within the next 12-18 months. If so, an acquisition price could be in the range of $150-$160 per share, with Roche (RHHBY) and Biogen (BIIB) possible suitors, Prasad tells investors.
09/12/17
MAXM
09/12/17
NO CHANGE
MAXM
Inovio data positive, says Maxim
Maxim analyst Jason McCarthy says that the data on Inovio's (INO) INO-5150 for prostate cancer indicates that the drug "holds promise." He thinks that the company may find a new partner to replace Roche (RHHBY), and he keeps a $12 price target and a Buy rating on the shares.
09/12/17
COWN
09/12/17
NO CHANGE
COWN
Cowen says cervical cancer recommendations a risk for Hologic, Becton Dickinson
Cowen analyst Doug Schenkel noted that the US Preventive Services Task Force recently released a draft recommendation on cervical cancer screening, which no longer recommends cotesting with both an HPV assay and cytology, which would be a negative for Hologic (HOLX) and Becton Dickinson (BDX) if the draft is implemented. If the draft is implemented, it is likely a positive for Roche (RHHBY), the only vendor with a primary screening HPV assay that is FDA approved, added Schenkel. However, the final recommendation statement can be materially different from the draft, he said.

TODAY'S FREE FLY STORIES

LKSD

LSC Communications

$13.92

-0.45 (-3.13%)

16:12
01/18/18
01/18
16:12
01/18/18
16:12
Hot Stocks
LSC Communications raises quarterly dividend 4% to 26c per share »

The board of directors of…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

SPRT

Support.com

$2.75

0.081 (3.03%)

16:11
01/18/18
01/18
16:11
01/18/18
16:11
Hot Stocks
Support.com reminds investors of net operating loss carryforwards »

Support.com reminded its…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MLNX

Mellanox

$65.10

0.8 (1.24%)

16:10
01/18/18
01/18
16:10
01/18/18
16:10
Technical Analysis
Technical Take: Mellanox at new 52-week high after results »

The shares are up over 4%…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jan

IBM

IBM

$169.07

0.59 (0.35%)

16:10
01/18/18
01/18
16:10
01/18/18
16:10
Hot Stocks
IBM reports Q4 Cognitive solutions revenue $5.4B, up 3% »

Reports Q4 Global…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jan

AMNB

American National Bankshares

$39.10

-0.8 (-2.01%)

16:10
01/18/18
01/18
16:10
01/18/18
16:10
Earnings
Breaking Earnings news story on American National Bankshares »

American National…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PINC

Premier

$32.23

-0.02 (-0.06%)

16:09
01/18/18
01/18
16:09
01/18/18
16:09
Initiation
Premier initiated  »

Premier initiated with an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CERN

Cerner

$69.49

-0.79 (-1.12%)

16:09
01/18/18
01/18
16:09
01/18/18
16:09
Initiation
Cerner initiated  »

Cerner initiated with an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Feb

QGEN

Qiagen

$32.59

-0.3 (-0.91%)

16:09
01/18/18
01/18
16:09
01/18/18
16:09
Hot Stocks
Qiagen granted FDA approval to expand use of EGFR test in lung cancer »

Qiagen announced that the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IBM

IBM

$169.21

0.73 (0.43%)

16:09
01/18/18
01/18
16:09
01/18/18
16:09
Hot Stocks
IBM reports Q4 cloud revenue $5.5B, up 30% »

Cloud revenue over the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jan

AXP

American Express

$99.88

-0.885 (-0.88%)

16:08
01/18/18
01/18
16:08
01/18/18
16:08
Hot Stocks
American Express reports Q4 U.S. Consumer Services up 13% to $3.4B »

U.S. Consumer Services…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jan

MDRX

Allscripts

$15.09

-0.21 (-1.37%)

16:08
01/18/18
01/18
16:08
01/18/18
16:08
Initiation
Allscripts initiated  »

Allscripts initiated with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Feb

IBM

IBM

$169.18

0.53 (0.31%)

16:08
01/18/18
01/18
16:08
01/18/18
16:08
Earnings
IBM reports Q4 adjusted EPS $5.18, consensus $5.17 »

Reports Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jan

ATHN

athenahealth

$125.53

-0.65 (-0.52%)

16:08
01/18/18
01/18
16:08
01/18/18
16:08
Initiation
athenahealth initiated  »

athenahealth initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Feb

MLNX

Mellanox

$65.10

0.8 (1.24%)

16:07
01/18/18
01/18
16:07
01/18/18
16:07
Earnings
Mellanox sees FY18 revenue $970M-$990M, consensus $971M »

Sees FY18 adjusted gross…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jan

MLNX

Mellanox

$65.10

0.8 (1.24%)

16:07
01/18/18
01/18
16:07
01/18/18
16:07
Earnings
Mellanox sees Q1 revenue $222M-$232M, consensus $220.3M »

Sees Q1 adjusted…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jan

AMGN

Amgen

$187.59

-0.42 (-0.22%)

, AGN

Allergan

$179.82

3.1 (1.75%)

16:06
01/18/18
01/18
16:06
01/18/18
16:06
Hot Stocks
Amgen and Allergan's Mvasi for certain cancers approved in Europe »

Amgen (AMGN) and Allergan…

AMGN

Amgen

$187.59

-0.42 (-0.22%)

AGN

Allergan

$179.82

3.1 (1.75%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jan

  • 25

    Jan

  • 25

    Jan

  • 03

    Feb

  • 06

    Feb

  • 16

    Feb

  • 08

    Mar

  • 25

    Mar

  • 23

    Apr

  • 30

    Apr

  • 17

    May

  • 28

    May

TXN

Texas Instruments

$116.41

-2.75 (-2.31%)

16:06
01/18/18
01/18
16:06
01/18/18
16:06
Hot Stocks
Texas Instruments: Brian Crutcher to become next CEO on June 1 »

Texas Instruments said…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

AXP

American Express

$99.90

-0.86 (-0.85%)

16:06
01/18/18
01/18
16:06
01/18/18
16:06
Earnings
Breaking Earnings news story on American Express »

American Express sees…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jan

MLNX

Mellanox

$65.10

0.8 (1.24%)

16:06
01/18/18
01/18
16:06
01/18/18
16:06
Earnings
Mellanox reports Q4 adjusted EPS 82c, consensus 68c »

Reports Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jan

AXP

American Express

$99.85

-0.9 (-0.89%)

16:06
01/18/18
01/18
16:06
01/18/18
16:06
Earnings
American Express reports Q4 adjusted EPS $1.58, consensus $1.54 »

Reports Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jan

TXN

Texas Instruments

$116.41

-2.75 (-2.31%)

16:05
01/18/18
01/18
16:05
01/18/18
16:05
Hot Stocks
Breaking Hot Stocks news story on Texas Instruments »

Texas Instruments: Brian…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

PBCT

People's United

$19.43

-0.02 (-0.10%)

16:04
01/18/18
01/18
16:04
01/18/18
16:04
Earnings
People's United reports Q4 operating EPS 31c, consensus 27c »

Q4 net interest margin…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jan

CRL

Charles River

$106.61

-0.16 (-0.15%)

16:04
01/18/18
01/18
16:04
01/18/18
16:04
Initiation
Charles River initiated  »

Charles River initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jan

IQV

Iqvia

$99.83

-0.395 (-0.39%)

16:04
01/18/18
01/18
16:04
01/18/18
16:04
Initiation
Iqvia initiated  »

Iqvia initiated with an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ICLR

Icon

$111.95

-0.93 (-0.82%)

16:04
01/18/18
01/18
16:04
01/18/18
16:04
Initiation
Icon initiated  »

Icon initiated with an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.